MEN1 family with a novel frameshift mutation

Journal of Endocrinological Investigation

Volumn 29, Issue 5, 2006, Pages 450-456

  Nuzzo, V ^a   Tauchmanove L ^a   Falchetti, A ^b   Faggiano, A ^a   Marini, F ^b   Piantadosi, S ^a   Brandi, M L ^b   Leopaldi, L ^a   Colao, A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cutaneous angiofibromas; Frame shift mutation; MEN1 syndrome; Menin; Octreoscan octreotide LAR; Primary hyperparathyroidism; Prolactinoma

Indexed keywords

CABERGOLINE; CHROMOGRANIN A; GASTRIN; GLUCAGON; GLUCOSE; OCTREOTIDE; PENTETREOTIDE IN 111; PROLACTIN;

ADRENAL CORTEX ADENOMA; ADRENALECTOMY; ADULT; ARTICLE; CASE REPORT; CAUCASIAN; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DNA SEQUENCE; EROSIVE GASTRITIS; EXON; EXPERIENCE; FACE DISORDER; FAMILY HISTORY; FAMILY STUDY; FRAMESHIFT MUTATION; GASTROINTESTINAL ENDOSCOPY; GENETIC ANALYSIS; GENETIC SCREENING; HEMANGIOFIBROMA; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HYPERPARATHYROIDISM; HYPERTENSION; HYPOPHYSIS; INTESTINE OBSTRUCTION; INTESTINE RESECTION; LIPOMA; MALE; MEDICAL SPECIALIST; MELENA; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PROLACTIN BLOOD LEVEL; SARCOMA; SCREENING TEST; SKIN TUMOR; STOMACH PAIN; TUMOR LOCALIZATION;

EID: 33745925858     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03344129     Document Type: Article

References (28)

1. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001, 86: 5658-71.
2. Schussheim DH, Skarulis MC, Agarwal SK, et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 2001, 12: 173-8.
3. Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med 1954, 16: 363-71.
4. Wermer P. Endocrine adenomatosis, peptic ulcer disease in a large kindered: inherited multiple tumors, mosaic pleiotropism in man. Am J Med 1963, 35: 205-8.
5. Larsson C, Skogseid B, Oberg K Nakamura Y, Nordenskjold M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988, 332: 85-7.
6. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997, 276: 404-7.
7. Agarwal SK, Lee Burns A, Sukhodolets KE, et al. Molecular pathology of the MEN1 gene. Ann N Y Acad Sci 2004, 1014: 189-98.
8. Jin S, Mao H, Schnepp RW, et al. Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res 2003, 63: 4204-10.
9. Kim H, Lee JE, Cho EJ, et al. Menin, a tumor suppressor, represses JunD mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. Cancer Res 2003, 63: 6135-9.
10. Schnepp RW, Hou Z, Wang H, et al. Functional interaction between tumor suppressor menin and activator of S-phase kinase. Cancer Res 2004, 64: 6791-6.
11. Sowa H, Kaji H, Hendy GN, et al. Menin is required for bone morphogenetic protein 2- and transforming growth factor beta-regulated osteoblastic differentiation through interaction with Smads and Runx2. J Biol Chem 2004, 279: 40267-75.
12. Agarwal SK, Kester MB, Debelenko LV, et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet 1997, 6: 1169-75.
13. Brandi ML. Multiple endocrine neoplasia type 1. Rev Endocr Metab Disord 2000, 1: 275-82.
14. Schussheim DH, Skarulis MC, Agarwal SK, et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 2001, 12: 173-8.
15. Glascock MJ, Carty SE. Multiple endocrine neoplasia type 1: fresh perspective on clinical features and penetrance. Surg Oncol 2002, 11: 143-50.
16. Ferolla P, Falchetti A, Rosso P, et al. Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series. J Clin Endocrinol Metab 2005, 90: 2603-8.
17. Trump D, Farren B, Wooding C, et al. Clinical studies of multiple endocrine neoplasia type I. Q J Med 1996, 89: 653-69.
18. Gibril F, Venzon DJ, Ojeaburu JV. Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab 2001, 86: 5282-93.
19. Skogseid B, Laesson C, Lindgren PG, et al. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type-1. J Clin Endocrinol Metab 1992, 75: 76-81.
20. Langer P, Cupisti K, Bartsch DK, et al. Adrenal involvement in multiple endocrine neoplasia type 1. World J Surg 2002, 26: 891-6.
21. Barzon L, Pasquali C, Grigoletto C, Pedrazzoli S, Boscaro M, Fallo F. Multiple endocrine neoplasia type 1 and adrenal lesions. J Urol 2001, 166: 24-7.
22. Burgess JR, Shepherd JJ, Parameswaran V, et al. Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN1): clinical, biochemical and radiological features of pituitary disease in a large MEN1 kindred. J Clin Endocrinol Metab 1996, 81: 2642-6.
23. Kaltsas GA, Bessere M, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004, 25: 458-511.
24. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991, 12: 450-82.
25. Kwekkeboom DJ, Krenning EP. Somatostatin receptors imaging. In: SWJ Lamberts, L Dogliotti eds. The expanding role of octreotide I: advances in oncology. Bristol: BioScientifica Ltd. 2002, 17-30.
26. Beckers A, Betea D, Valdes Socin H, Stevenaert A. The treatment of sporadic versus MEN-I related pituitary adenomas. J Intern Med 2003, 253: 599-605.
27. Verges B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multi-center study. J Clin Endocrinol Metab 2002, 87: 457-65.
28. Shi W, Buchanan KD, Johnston CF, et al. The octreoscan suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment. Clin Endocrinol (Oxf) 1998, 48: 303-9.